Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06705478CT.gov Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV | — | Recruiting | — | — | — |
NCT05322031CT.gov The Impact of Aripiprazole Long-acting on Myelin and Cognition in the Onset of Schizophrenia | — | Completed | — | — | — |
NCT01876823CT.gov Memantine Plus Es-citalopram in Elderly Depressed Patients With Cognitive Impairment | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cognitive Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Escitalopram (this asset) | National Institute of Allergy and Infectious Diseases (NIAID) | Approved | BB · 65 |
| Nicotine | University of Southern California | P2 | BBB |
| Oxybutynin | University of Alberta | P4 | BBB |
| Levodopa | Vanderbilt University Medical Center | P4 | BB |
| Rivastigmine | VA Office of Research and Development | P4 | BB |
| Metformin | Fudan University | P4 | BB |
| Memantine | UNC Lineberger Comprehensive Cancer Center | P3 | BB |
| Ginkgo Biloba | Dr. Willmar Schwabe GmbH & Co. KG | P4 | BB |
| Ginkgo Biloba Extract | Hanyang University | P4 | BB |
+42 more in the Cognitive Disorder cohort
Other indications for Escitalopram
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Bipolar I Disorder | — | P4 | BBB · 77 |
| Dysthymic Disorder | — | P4 | BBB · 76 |
| Depressive Disorder | — | P4 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Escitalopram in Cognitive Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/escitalopram-cognitive-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →